NCT03278782 2026-01-09Study of Pembrolizumab (MK-3475) in Combination With RomidepsinM.D. Anderson Cancer CenterPhase 1/2 Active not recruiting39 enrolled
NCT03432741 2025-05-26Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerMayo ClinicPhase 1 Terminated17 enrolled
NCT04774068 2025-01-17Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell LymphomasOhio State University Comprehensive Cancer CenterPhase 1 Completed5 enrolled